for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nektar Therapeutics

NKTR.O

Latest Trade

15.87USD

Change

-0.00(-0.00%)

Volume

2,738,785

Today's Range

15.70

 - 

17.10

52 Week Range

15.70

 - 

51.28

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.87
Open
17.08
Volume
2,738,785
3M AVG Volume
80.45
Today's High
17.10
Today's Low
15.70
52 Week High
51.28
52 Week Low
15.70
Shares Out (MIL)
175.27
Market Cap (MIL)
2,995.44
Forward P/E
-5.94
Dividend (Yield %)
--

Next Event

Q3 2019 Nektar Therapeutics Earnings Release

Latest Developments

More

Nektar Therapeutics Q2 Loss Per Share $0.63

Nektar Therapeutics And Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation For Bempegaldesleukin (NKTR-214) In Combination With Opdivo (Nivolumab)

Nektar Therapeutics Receives A General Advice Letter From U.S. Food And Drug Administration

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Industry

Biotechnology & Drugs

Contact Info

455 Mission Bay Blvd S

+1.415.4825300

http://www.nektar.com

Executive Leadership

Robert B. Chess

Independent Chairman of the Board

Howard W. Robin

President, Chief Executive Officer, Director

Gilbert M. Labrucherie

Chief Financial Officer, Chief Operating Officer, Senior Vice President

Jillian B. Thomsen

Senior Vice President - Finance, Chief Accounting Officer

Wei Lin

Senior Vice President - Clinical Development and Head of Nektar's Oncology Programs

Key Stats

2.38 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.2K

2017

0.3K

2018

1.2K

2019(E)

0.1K
EPS (USD)

2016

-1.100

2017

-0.620

2018

3.780

2019(E)

-2.876
Price To Earnings (TTM)
--
Price To Sales (TTM)
25.15
Price To Book (MRQ)
1.92
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
15.91
LT Debt To Equity (MRQ)
15.91
Return on Investment (TTM)
-20.12
Return on Equity (TTM)
-19.16

Latest News

Latest News

Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study.

Mixed results for Bristol/Nektar combination in cancer trial

Mixed results over the weekend from closely watched studies combining Bristol-Myers Squibb Co's cancer immunotherapy with Nektar Therapeutics experimental drug NKTR-214, led at least one Wall Street analyst to reassess expectations.

BRIEF-Nektar Therapeutics Says CEO Howard W. Robin's 2017 Total Compensation Was $18.1 Million

* NEKTAR THERAPEUTICS SAYS CEO HOWARD W. ROBIN'S 2017 TOTAL COMPENSATION WAS $18.1 MILLION – SEC FILING

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21

* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007 Source text: (http://bit.ly/2BsgSdG) Further company coverage:

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN Source text (http://bit.ly/2zxBcXv) Further company coverage:

BRIEF-Nektar Therapeutics reports Q3 earnings per share $0.39

* Nektar Therapeutics reports financial results for the third quarter of 2017

BRIEF-Nektar Therapeutics presents preclinical data on NKTR-358

* Presents preclinical data on NKTR-358, a first-in-class regulatory T Cell stimulator, at 2017 American College of Rheumatology Annual Meeting Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics initiates propel clinical study

* Nektar Therapeutics initiates propel clinical study to evaluate combination of NKTR-214, a CD122-biased agonist, with tecentriq (atezolizumab) or keytruda (pembrolizumab) Source text for Eikon: Further company coverage:

BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement

* Nektar Therapeutics - Co, Eli Lilly got notice of early termination of waiting period related to license agreement to co-develop NKTR-358 - SEC filing Source text:[http://bit.ly/2wFqKyD] Further company coverage:

BRIEF-Nektar Therapeutics Q2 loss per share $0.39

* Nektar therapeutics reports financial results for the second quarter of 2017

BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358

* Lilly and Nektar Therapeutics announce alliance to develop and commercialize NKTR-358, an autoimmune therapy

EMA panel recommends against Nektar, Daiichi Sankyo's breast cancer drug

European regulators on Friday recommended against granting approval to a breast cancer drug being developed by Nektar Therapeutics and Daiichi Sankyo's German unit.

BRIEF-Nektar presents findings from two phase 1 clinical studies of NKTR-214

* Presented new findings from two phase 1 clinical studies of NKTR-214, nektar's lead immuno-oncology candidate

BRIEF-Nektar Therapeutics reports Q1 revenue $24.7 million

* Nektar Therapeutics reports financial results for the first quarter of 2017

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up